Advertisement

Topics

Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 Pipeline Review, H1 2017

Summary

According to the recently published report 'Caspase 6 Pipeline Review, H1 2017'; Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 Caspase6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly ADPribose polymerase.

The report 'Caspase 6 Pipeline Review, H1 2017' outlays comprehensive information on the Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer's Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure Hepatic Insufficiency, Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease NAFLD, NonAlcoholic Steatohepatitis NASH, Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59
The report reviews Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 targeted therapeutics and enlists all their major and minor projects
The report assesses Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Caspase 6 Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59 Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...